Earnings Call Excerpt
Biogen Idec Inc. (BIIB)
Q2 2009 Earnings Call
July 16, 2009 8:30 am ET
Executives
James C. Mullen - Chief Executive Officer
Dr. Al Sandrock - Senior Vice President, Neurology R&D
Robert Hamm - Chief Operating Officer
Paul J. Clancy - Chief Financial Officer and Executive Vice President of Finance
Eric S. Hoffman, PhD. - Investor Relations
Analysts
May-Kin Ho - Goldman Sachs
Eric Schmidt - Cowen & Co.
Steven Harr - Morgan Stanley
Bret Holley - Oppenheimer & Co.
Jim Birchenough - Barclays Capital
Michael Aberman - Credit Suisse
Mark Schoenebaum - Deutsche Bank Securities
Kareem De Felipe - Citigroup
Geoffrey Porges - Sanford Bernstein
Geoff Meecham - J.P. Morgan
Eun Yang - Jefferies
Joel Sendek - Lazard Capital Markets
Ian Somaiya - Thomas Weisel Partners
Jason Zhang - BMO Capital
Maged Shenouda - UBS
Josh Schimmer - Leerink Swann
Presentation
Operator
Good morning my name is Celeste and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Idec’s second quarter 2009 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. (Operator Instructions). Mr. Hoffman you may now begin your conference.
Eric S. Hoffman
Welcome to Biogen Idec’s second quarter 2009 earnings conference call. Before we begin, I’d encourage everyone to go to Investor Relations website to find the press release and related financial tables including reconciliation of the non-GAAP financial measures that we’ll discussed today. We have also posted slides on our website that outline the topics discussed on today’s call.
As usual, we’ll start with the Safe Harbor statement. Comments made in this conference call include forward-looking statements about our expected future results including our 2009 financial guidance, our longer-term operational and financial goals, the sales potential of Tysabri and other products and pipeline advancements.
These statements are subject to risks and uncertainties which could cause actual results to differ materially from expectations. You should carefully review the risks and uncertainties that are described in our earnings release, and in Item 1A of our most recent annual and quarterly reports filed with the SEC. We do not undertake any obligation to publicly update any forward-looking statements.
Today on the call I’m joined by Jim Mullen, CEO of Biogen Idec; Dr. Al Sandrock, Senior Vice President Neurology R&D; Bob Hamm, Chief Operating Officer; and Paul Clancy, CFO and Executive Vice President of Finance.
- To read the full transcript on Seeking Alpha, click here »
